Gilead Sciences (GILD) has been in focus after agreeing to a US$45 million settlement with the Texas Attorney General, closing Medicaid fraud allegations tied to prescribing incentives for its medicines.
Gilead Sciences has been trading with firm momentum, with the share price at US$158.69 after a 1-day share price return of 1.70%, a 7-day share price return of 3.67% and a 90-day share price return of 18.14%, against a backdrop of fresh HIV, liver disease and oncology data updates and the Texas Medicaid settlement. Over a longer horizon, the 1-year total shareholder return of 34.98% and 5-year total shareholder return of 188.88% point to a trend in which recent gains build on already strong compounding for long-term holders.
Spot fresh momentum stories like Gilead Sciences by scanning our hand-picked 29 high quality undervalued stocks, which pairs solid fundamentals with recent price strength.After a run like this and fresh headlines on both products and legal risk, Gilead Sciences invites a simple fork in the road. Does it make sense to step in now or wait for a clearer discount?
Most Popular Narrative: 24% Overvalued
The most followed narrative on Gilead Sciences pegs fair value at $128.38, below the last close of $158.69. This frames the recent rally as rich against that reference point while still anchored in the same underlying pipeline story investors are reacting to.
Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers (lenacapavir, Trodelvy) and high-upside optionality (cell therapy, immunology). Temporary earnings headwinds may be masking long-term value creation as management leans into acquisitions and late-stage programs that are not yet fully reflected in headline profitability.
See why 19 investors see Gilead Sciences as 24% overvalued.
Result: Fair Value of $128.38 (OVERVALUED)
Still, the Gilead Sciences story can break if key oncology readouts disappoint or if acquisition integration weighs on earnings longer than investors expect.
Find out about the key risks to this Gilead Sciences narrative.
Another View: Multiples Point To Undervaluation
That user narrative pegs Gilead Sciences as 24% overvalued at $128.38, yet our SWS checks using the P/S yardstick tell a different story. The shares trade at 6.5x sales compared with 10.7x for the US Biotechs industry and 7.4x for peers. The fair ratio sits even higher at 11.5x. That gap suggests investors are still pricing in a margin of safety rather than over-exuberance. Which story do you trust when momentum and valuation pull in opposite directions?
See what the numbers say about this price, find out in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on Gilead Sciences so far, or a clear opportunity hiding in plain sight. Act while the data is fresh and weigh the balance of risk and reward for yourself by checking the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Gilead Sciences?
Gilead Sciences may be top of mind today, but your next strong idea probably comes from widening the search and stress-testing a few very different opportunities.
- Target resilient cash generators by scanning a list of solid balance sheet and fundamentals (24 results) that filters for businesses built to handle shocks without stretching their finances.
- Hunt for potential mispricing by working through a curated 29 high quality undervalued stocks that couples quality fundamentals with prices that still look restrained.
- Build a steadier income stream by reviewing a hand-picked 5 dividend fortresses focused on higher-yield payouts with an eye on durability.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com